Verona Pharma plc (VRNA) Financial Analysis & Valuation | Quarter Chart
Verona Pharma plc (VRNA)
VRNAPrice: $106.91
Fair Value: 🔒
🔒score
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (P... more
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercial... more
Description
Shares
| Market Cap | $72.68B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | David S. Zaccardelli |
| IPO Date | 2017-04-28 | CAGR | — |
| Employees | 209 | Website | www.veronapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.15% | Total Yield | 0.15% |
VRNA chart loading...
Fundamentals
Technicals
| Enterprise Value | $7.91B | P/E Ratio | -102.8 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 444.67 | P/B Ratio | 32.9 |
| P/CF Ratio | -930.9 | P/FCF Ratio | -7008.07 |
| EPS | $-1.04 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 0.95% |
| Operating Margin | -0.08% | Profit Margin | -0.19% |
| ROE | -0.13% | ROA | -0.05% |
| ROCE | -0.02% | Current Ratio | 10.71 |
| Quick Ratio | 10.54 | Cash Ratio | 8.55 |
| Debt/Equity | 0.88 | Interest Coverage | -0.47 |
| Altman Z Score | 109.91 | Piotroski Score | 3 |